Biopharmaceutical company Basking Biosciences has revealed positive Phase I study results for its reversible thrombolytic therapeutic for ischaemic stroke. The company’s novel von Willebrand Factor (vWF)-targeting thrombolytic agent, BB-031 demonstrated safety and tolerability following a single intravenous dose. The study results were presented at the American Heart Association International Stroke Conference (ISC) 2023 in Dallas, […]
Menu ≡ ╳ 
